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Abstract. 
X-linked Intellectual Disabilities (XLID) are common developmental disorders. The 
enzyme O-GlcNAc transferase encoded by OGT, a recently discovered XLID gene, 
attaches O-GlcNAc to nuclear and cytoplasmic proteins. As few missense mutations 
have been described, it is unclear what the aetiology of the patient phenotypes is. Here, 
we report the discovery of a missense mutation in the catalytic domain of OGT in an XLID 
patient. X-ray crystallography reveals that this variant leads to structural rearrangements 
in the catalytic domain. The mutation reduces in vitro OGT activity on substrate 
peptides/protein. Mouse embryonic stem cells carrying the mutation reveal reduced O-
GlcNAcase (OGA) and global O-GlcNAc levels. These data suggest a direct link between 
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Introduction 
Intellectual disability (ID) is a neurodevelopmental disorder, with a world-wide prevalence 
of 1% [1],  characterised by significant limitations in both intellectual functioning and 
adaptive behaviour [2]. ID is often syndromic, involving not only a limited IQ but also 
developmental delay, congenital malformations or neurological abnormalities such as 
autism spectrum disorder (ASD), epilepsy, and sensory impairment [3–8]. Although ID 
can be caused by environmental factors such as maternal alcohol abuse and birth 
complications [6,8,9], genetics plays a crucial role in its aetiology. Mutations, deletions or 
rearrangements affecting genes involved in development and neuronal function can have 
severe consequences for proper brain development or cognitive function [10]. 
To date, approximately 1000 genes have been shown to be involved in ID [11].  A 
disproportionate number (141) of these are located on the X-chromosome, leading to the 
coining of the term X-linked intellectual disability (XLID) [5] . In the last few years, next-
generation sequencing (NGS) has led to enormous progress in deciphering monogenic 
forms of XLID [3–5,10]. This unbiased NGS approach has accelerated identification of de 
novo mutations in newly described XLID genes, including OGT, which encodes O- β-N-
acetylglucosamine (GlcNAc) Transferase (OGT). 
OGT catalyses an essential post-transitional modification, the addition of a single 
GlcNAc onto serine or threonine of nucleocytoplasmic proteins, using UDP-GlcNAc as 
donor substrate [12]. OGT is also known to be involved in the processing of the Host Cell 
Factor C1 (HCF1), the proteolytic products of which are involved in the activation of many 
genes involved in cell cycle progression [13–15]. The enzyme is divided into a 
glycosyltransferase catalytic domain and an N-terminal domain consisting of 13.5 
tetratricopeptide repeats (TPRs) that have been shown to contribute to protein substrate 
binding [16–18]. Together with the hydrolase O-GlcNAcase (OGA), the homeostasis of 
dynamic protein O-GlcNAcylation is maintained for optimal cellular function [19]. Effects 
of protein O-GlcNAcylation have been linked to protein synthesis [20], stability [21] and 
turnover [22,23] and complex processes such as cell cycle progression [24], stress 
response [25,26], and transcription [27]. O-GlcNAcylation has also been implicated in 
pathology, including cancer [28], type II diabetes [29], cardiovascular disease [30] and 
neurodegeneration [31], and it is essential for proper vertebrate development [32–35]. In 
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processes in early development. In mice, Ogt knockout causes lethality, with mouse 
embryos dying at the blastocyst stage [36]. 
O-GlcNAcylation also plays a key role in stem cell biology. Numerous pluripotency 
factors such as Oct4 and Sox2 have been shown to be O-GlcNAcylated [33,37]. 
Furthermore, mutations in OGT trigger alterations in stem cell differentiation and 
development, affecting neuronal lineages [37,38]. To date, five OGT mutations, all 
located to the N-terminal TPR domain, have been reported in patients with XLID [39–42]. 
These patients display developmental delay, facial dysmorphia, clinodactyly and 
microcephaly. To date, it is not clear whether the underpinning mechanisms leading to 
these phenotypes involve changes in the O-GlcNAc proteome. 
Here, we report a patient with moderate ID, coarse facial features and a de novo 
mutation located in the catalytic domain of OGT. This mutation induces structural 
rearrangements in the catalytic domain, leading to reduced levels of protein O-
GlcNAcylation in vitro and in mESCs, suggesting a direct link between perturbations in 
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Results and Discussion
A patient with XLID possesses a missense mutation in the OGT catalytic domain
The patient, E.T., was born at term with normal birth weight; 3354 g, length; 50 cm, head 
circumference; 34.5 cm, and an Apgar score of 9/9. He is the second child of an Estonian 
non-consanguineous family. His elder brother is healthy. Facial asymmetry was noticed 
soon after birth (Fig. 1A). His toenails were also very small and with soft structure at 
birth. His development was evaluated as normal during the first months of life; he started 
to hold his head at 3 m and to turn at 6 m of age. Initially, he also had good weight gain, 
but after some months gastric reflux and gasses became very problematic. 
Recurrent otitis started at 4 m and after narcosis (the shunting of middle ears) his 
development arrested. His muscular tone became very flaccid. He started to turn at 12 m, 
to crawl at 14 m, to sit at 22 m, and to walk at 3 y of age. First teeth came very late and 
slowly at 12 m. At the age of 16m alimentary vitamin B12 deficiency was diagnosed and 
treated with intramuscular injections. After that his development improved significantly. 
However, at the age of 19 m persistent otitis recurred and his development arrested. 
He was subjected to extensive clinical investigation at 19 m due to his 
developmental delay. He had coarse facial features with open mouth and drooling. He 
suffered from hypotonia with brisk tendon reflexes and truncal ataxia. There was a 
suspicion of epilepsy, but EEG was normal. Brain MRI was normal for that age. On 
cardiac evaluation only very mild pericardial effusion was noticed, which did not affect 
cardiac function. Griffith scale evaluation suggested that his development corresponded 
to 8 m of age. He had serious problems with obstipation, but no obvious aetiology was 
detected. Extensive metabolic investigations were performed, which showed normal 
results (urinary organic acids, glycosaminoglycans, oligosaccharides, sialic acid, 
creatine/guanidinoacetate, and purine/pyrimidines; transferrin isoelectric focusing (TIEF) 
and acylcarnitine in serum; neurotransmitters in cerebrospinal fluid). Chromosomal 
microarray analysis showed no abnormal copy number variations.
At the age of 7 y 8 m his height was 127 cm (+1 SD), weight 23.4 kg (0 SD), head 
circumference 52 cm (-0.5 SD). He is moderately intellectually disabled. He had coarse 
facial features, convergent strabismus, large ears and intense and constant drooling (Fig. 
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increased sensibility to light and sounds, and fears. In addition, he had hyper-elastic 
connective tissue, which manifested as frequent joint dislocations and scoliosis. He 
presented mild T2-3 syndactyly, inverted nipples, abnormally pale skin and body 
temperature fluctuations in addition to his frequent infections. X-ray investigation showed 
cone shape epiphyses of T2-T5 (Fig. 1D), fragmentation of the 1st rib and synostosis of 
1-2 ribs. Brain MRI investigation at 5 y showed brain atrophy and mega cisterna magna 
(Fig. 1C). Ophthalmological investigation revealed astigmatism and myopia.
Biochemical analyses showed repeatedly increased thyroglobulin (45-48 µg/L; 
normal 5-43) and follicle stimulating hormone (3.5-3.9 U/L; normal < 3). All other 
hormonal analysis and coagulation factors were in normal range. Immunological analysis 
showed repeatedly low percentage of activated T lymphocytes (1.4-2.1; normal 2.3-7.0 
%) and mildly low CD8 T cells % (18 %; normal 19-34). TIEF analysis of the serum has 
been repeatedly performed with normal profile result.
Trio whole genome sequencing was performed. After variant filtration for de novo, 
recessive or X-linked variants with allele frequencies below 1%, we identified a missense 
variant in the OGT gene ChrX (GRCh38): g.71561865A>T; NM_181672.2: c.1942A>T 
p.(Asn648Tyr). Both parents and sibling were healthy and did not carry this mutation. 
Unlike the other OGT XLID mutations identified to date, this mutation maps to the 
catalytic domain of OGT (Fig. 2A)
The N648Y mutation leads to structural changes in the catalytic domain
Asn648 is highly conserved in OGT from C. elegans to H. sapiens (Supplementary Fig. 
1). Inspection of the human OGT crystal structure reveals that Asn648 maps to the 
interface of the OGT TPRs with the catalytic domain. The Asn648 side chain forms van 
der Waals interactions with that of Tyr642, while the loop between these two interacting 
residues (hereafter 642-648 loop) forms part of the composite OGT acceptor substrate 
binding cleft. It is thus possible that this mutation could affect the TPR-catalytic domain 
interface and lead to changes in the stability of the protein. We first analysed the effect of 
the mutation on the folding stability using differential scanning fluorimetry. Using an E. 
coli expression system, we purified a recombinant truncated form of OGT version 
containing the catalytic domain and 3.5 TPR repeats, for both wild type (OGTWT) and 
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for both OGTWT and OGTN648Y with inflection points (Tm) of 44 °C, indicative of identical 
unfolding temperatures (Supplementary Fig S2). Given that the mutation has the 
potential to alter the 642-648 loop, which forms an important part of the catalytic pocket, 
we next investigated possible structural changes by X-ray crystallography. Recombinant 
OGTN648Y was crystallised in presence of the donor substrate analogue UDP-5S-GlcNAc 
and an acceptor peptide derived from the well-characterised OGT substrate TGF-beta-
activated kinase 1 binding protein 1 (TAB1). Diffraction data were collected to 2.2 Å and 
initial refinement started from the published OGTWT ternary structure [43]. Mutation of 
Asn648 to the bulkier tyrosine appears to be accommodated without disruption of the 
domain organisation observed in the wild type structure (RMSD of 0.4 Å on all backbone 
C atoms) (Fig. 2B). However, the aromatic Tyr648 side chain forms a - stacking 
interaction with Tyr642 causing positional shifts of up to 0.7 Å in the 642-648 loop. 
Strikingly, despite the presence of an acceptor peptide in the crystallisation condition, no 
corresponding electron density was observed in the OGT active site. This could be 
because the changes in 642-648 loop caused by the mutation affects the ability of OGT 
to bind to acceptor substrates (Fig. 2C). To explore this possibility, we used a recently 
established fluorescence polarimetry assay (FP) where increasing concentrations of OGT 
are titrated against a fixed concentration of a fluorescent probe that incorporated 
elements of both peptide and nucleotide substrates [44]. The direct binding affinity of the 
probe to OGTWT yielded a Kd value of 1.6 µM as previously reported, whereas the Kd 
value for the OGTN648Y was 7 times higher (11 µM), suggesting reduced substrate binding 
in agreement with the structural observations (Fig. 2D).   In summary, the N648Y 
mutation may lead to changes in the OGT acceptor substrate binding cleft and affect 
substrate binding. 
OGTN648Y does not glycosylate the model acceptor substrate TAB1 
Given the absence of effects on stability and the apparent effect of the N648Y mutation in 
OGT substrate-binding, it is possible that catalytic activity is affected. To investigate this, 
we used an enzyme assay where we incubated OGTWT or OGTN648Y with the well 
characterised substrate TAB1. This substrate is efficiently mono-glycosylated on Ser395 
by wild type OGT [45]. Western blotting analysis using a specific antibody which binds 









This article is protected by copyright. All rights reserved
glycosylate the substrate (Fig. 2E), in contrast to the efficient glycosylation observed by 
OGTWT. Thus, OGTN648Y does not glycosylate the model acceptor substrate TAB1.
The N648Y mutation leads to hypo-glycosylation in mES cells
Maintenance of O-GlcNAc homeostasis is essential for optimal cellular function, and 
perturbations in protein O-GlcNAcylation have been implicated in pathogenesis. We next 
investigated the effects of reduced OGTN648Y activity on O-GlcNAc homeostasis and 
levels of OGA/OGT. We used CRISPR/Cas9 genome editing to introduce the N648Y 
mutation in the endogenous ogt locus carrying an additional N-terminal triple HA (3HA) 
tag (as described in detail in Materials and Methods). Two independent clones each 
were obtained for mESCs carrying 3HA-tagged wild type and 3HA-tagged mutant OGT, 
as verified by diagnostic restriction digest and sequencing. Western blotting analyses of 
3HA-N648Y mESC cells was carried out to analyse OGT, OGA and protein O-
GlcNAcylation levels (Fig. 3A). In agreement with loss of in vitro activity towards the 
TAB1 substrate (Fig. 2E) and the potential effect of the loop 642-648 on OGT substrate 
binding (Fig. 2D), this experiment revealed significantly reduced O-GlcNAc levels in 3HA-
N648Y mESCs compared to the controls. This is evidence for a possible link between 
perturbation in protein O-GlcNAcylation and XLID. No reduction in OGT protein levels 
were detected. However, OGA levels appeared reduced in 3HA-N648Y mESCs (Fig. 
3B). This hints at the existence of a compensatory mechanism that allows cells to 
partially maintain O-GlcNAc homeostasis by reducing OGA levels – as also observed in 
some of the other OGT XLID mutations in the TPR domain [39,46]. Thus, the N648Y 











This article is protected by copyright. All rights reserved
Concluding remarks 
Protein O-GlcNAcylation has emerged as an essential PTM involved in disease, and 
more recently in neuronal function and development [19,32,33,41]. Recent NGS studies 
have led to the identification of mutations in OGT that give rise to XLID, suggesting a 
direct link between O-GlcNAc and regulation of brain development. However, 
experimental evidence for a link between significant loss of OGT activity and changes in 
the O-GlcNAc proteome has remained elusive, presumably because of the location of 
these mutations in the N-terminal TPR substrate binding domain of OGT. Here, we report 
a patient with XLID attributable to an OGT missense mutation (Asp648Tyr), which maps 
to the OGT catalytic domain (Fig. 2A). In agreement with the five previously reported 
patients, the patient shows reduced IQ, limited speech, developmental delay, facial 
dysmorphia and hypotonia. 
  We initially delineated the effects of the mutation on the stability, structure and 
activity of the enzyme using in vitro approaches. Unlike the previously reported OGT 
XLID mutations we were not able to detect changes in folding stability induced by the 
mutation (Supplementary Fig. 2). Using X-ray crystallography, we revealed that the 
mutation did not induce large global conformational changes. However, the observed 
local conformational changes in the OGT acceptor substrate binding cleft could affect 
activity. Indeed, using in vitro analyses, the mutant led to significant reduction in the 
binding affinity of a bisubstrate fluorescence polarimetry probe and defects in the 
glycosylation of TAB1, suggesting a direct effect of the mutation on enzymatic activity 
(Fig. 2D and E)
To extend our investigations, we introduced the patient mutation into a male 
mouse embryonic stem cell line. In previous studies, examination of the steady-state 
global OGT, OGA and O-GlcNAc levels in different cell lines showed no significant 
changes in protein O-GlcNAc and OGT, while OGA levels appeared reduced in most of 
the analysed cell lines, suggesting a compensatory mechanism between OGT and OGA 
to maintain O-GlcNAc homeostasis (Fig. 3). To our surprise, the 3HA-N648Y mESC lines 
showed not only reduced levels of OGA, but also reduced protein O-GlcNAcylation 
levels. This suggests that perturbations in O-GlcNAc cycling may contribute to the patient 
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whose altered O-GlcNAcylation levels can be linked to cellular processes that could be 
causative for the observed phenotypes.
There is currently only a very limited number (six) of XLID patients identified that 
carry different mutations in ogt. It is thus not yet feasible to consider possible treatments. 
An interesting clue to a possible treatment is the observed changes in OGA levels. This is 
a mechanism that may compensate for loss in OGT activity or protein levels. This would 
lead to the hypothesis that (further) inhibition of OGA is a possible route towards re-
establishing full O-GlcNAc homeostasis and possible alleviation of the patient 
phenotypes. Another route would be to increase cellular production of UDP-GlcNAc, 
which has been shown to directly lead to increased levels of protein O-GlcNAcylation. It 
has been demonstrated that this is possible to achieve by feeding cells with the UDP-
GlcNAc precursor glucosamine, which enters the hexosamine biosynthetic pathway as 
glucosamine-6-phosphate and leads to increased UDP-GlcNAc levels [47–50].  
Glucosamine, in the form of glucosamine sulphate, is a food supplement frequently taken 
by patients suffering from osteoarthritis, albeit with limited clinical evidence for significant 
benefits [51,52]. In an initial experiment, at the age of 8 y of our patient we started the 
treatment with glucosamine sulphate (400 mg three times a day). This treatment has 
been performed over a period of 13 m without any adverse effects (unpublished data). 
Parents have noticed that the patient is more active; he has more energy and has 
increased plasticity in movements. He started to use syllables and teeth development 
progressed. However, there are no changes in clinical biochemical analyses, and in the 
absence of a proper randomised trial it is not possible to attribute these improvements to 
the treatments. Nevertheless, this is an approach that could be evaluated once sufficient 
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Materials & Methods
Whole genome sequencing
Trio whole genome sequencing and data processing were performed by Genomics 
Platform at the Broad Institute of Harvard and MIT (Broad Institute, Cambridge, MA, 
USA). The variant filtration for de novo, recessive or X-linked variants with allele 
frequencies below 1% in ExAC and gnomAD databases revealed three high quality 
variants, all appearing hemizygous on X-chromosome in genes DLG3, OGT, KIAA1210. 
Out of them the OGT variant ChrX(GRCh38): g.71561865A>T; NM_181672.2: 
c.1942A>T p.(Asn648Tyr) was the only variant with no hemizygous carriers in ExAC, 
gnomAD and in-house database, and thus considered as the most probable candidate 
after variant filtration. The variant appeared as de novo in protein domain: O-GlcNAc 
transferase, C-terminal. The variant was validated by Sanger sequencing. The mutated 
p.Asn648 amino acid is highly conserved from man to C. elegans, and multiple in-silico 
pathogenicity predicting algorithms indicated a damaging effect. Pathogenicity classified 
by the American College of Medical Genetics variant interpretation guidelines is likely 
pathogenic (absent from population databases, multiple computational evidence, de 
novo).
Protein expression and purification
Truncated (323-1044) OGT constructs were expressed in E. coli BL21(DE3) RIPL cells 
as N-terminal GST fusion protein, as described previously [43]. Briefly, transformed E. 
coli cells were grown in LB broth at 37 °C with agitation until OD600 reached 0.8, at which 
point the temperature was lowered to 18 °C and expression was induced by addition of 
100 µM IPTG. Cells were lysed using French Press in base buffer (0.1 M Tris-HCl, pH 
7.5, 0.15 M NaCl, 0.5 mM TCEP) supplemented with 25 mM imidazole 0.1 mg/ml DNase 
I and protease inhibitor cocktail (1 mM benzamidine, 0.2 mM PMSF, 5 mM leupeptin). 
Then, recombinant proteins were affinity purified following manufacturers’ guidelines. 
After cleavage of affinity tags, dialyzed protein was loaded onto 5 ml HiTrap Q Sepharose 
FF anion exchange resin (GE Healthcare) and eluted with a linear gradient up to 60% of 
buffer B (0.1 M Tris-HCl, pH 8.5, 500 mM NaCl). Peak fractions were pooled, 
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SuperdexTM 200 column (GE Healthcare) equilibrated with base buffer. The peak 
fractions were concentrated to 10 mg/ml. For crystallisation, truncated mutant OGT was 
used fresh at 7 mg/ml concentration. For all other purposes, proteins were concentrated 
to 10 mg/ml, mixed 1:1 with 50% glycerol, snap-frozen and stored at -80 ˚C until use. 
Structure solution
Crystallisation of truncated OGTN648Y (residues 323-1044) was performed as described 
previously [43]. Briefly, experiments were performed at 22 ºC using 24-well hanging drop 
crystallization plates, by combining 1 µl drops containing 7 mg/ml OGTN648Y (in base 
buffer), 3 mM UDP-5S-GlcNAc and 3 mM acceptor peptide derived from TAB1 sequence 
(PVSVPYSSAQSTS) with 2 µl of reservoir solution (1.45 M K2HPO4, 8 mM EDTA and 1% 
xylitol. Large, clear-faced crystals appeared overnight. Prior to diffraction experiments, 
individual crystals were cryo-protected in reservoir solution supplemented with 3.5 M 
maleic acid, 3 mM UDP-5S-GlcNAc and 3 mM acceptor peptide and flash-frozen in liquid 
nitrogen. Diffraction data were collected at the European Synchrotron Radiation Facility 
beamline ID23. Data were processed with XDS [53] and scaled to 2.2 Å using SCALA 
[54]. The structure was solved by molecular replacement using the structure for OGTWT 
(PDB: 5C1D;[43]) as the search model. The resulting model was manually refined using 
Coot [54] and REFMAC [55], respectively. Although the mutant protein was crystallised in 
the presence of donor and acceptor, there was no evidence for the latter in the electron 
density maps and was therefore excluded from the model. Coordinates and structure 
factors were deposited in the PDB (PDB:6Q4M). Scaling and model building statistics 
can be seen in Table 1. 
Fluorescence polarimetry assay. 
To evaluate the expected binding differences between the OGTWT and the OGTN648Y we 
titrated a previously published fluorescently labelled UDP-peptide bisubstrate conjugate 
[56]   with increasing concentrations of either OGTWT or the OGTN648Y in 0.1 M Tris-HCl 
pH 7.5, 0.15 M NaCl, 0.5 mM TCEP and 5% DMSO. Each sample, containing 25 𝜇l was 
incubated in the dark for 30 min before the read-out with a PHERAStar plate reader 
(BMG LABTECH). Subsequent data analysis was performed using GraphPad Prism 6 as 
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Activity assays
O-GlcNAcylation assays were performed on TAB1 protein (residues 7-420). TAB1 (1 µM) 
was combined with full length OGTWT or OGTN648Y (0.1 µM) in the presence of 100 µM 
UDP-GlcNAc. The reaction mixtures were incubated at 37 ºC for 2 to 50 minutes and 
subsequently stopped by addition of LDS loading buffer (4x, Thermo Fisher Scientific). 
Proteins were resolved by SDS-PAGE (4-12% acrylamide [Life Technologies]) and 
transferred onto nitrocellulose membranes (GE Healthcare). After antibody treatment, 
progress of the reaction was visualised using LI-COR Odyssey scanner and associated 
quantification software.
Mouse ES Cell culture
mESC E14-TG2a.IV AW2 line was acquired from the MRC Centre for Regenerative 
Medicine, Institute for Stem Cell Research, University of Edinburgh [57]. mESCs were 
cultured in an undifferentiated state in 0.1% gelatin [w/v] coated plates in GMEM BHK-21 
(Gibco) supplemented with 10% FBS [v/v] (Gibco), 0.1 mM MEM non-essential amino 
acids (Gibco), 1 mM sodium pyruvate (Gibco), 0.1 mM 2-mercaptoethanol (Gibco) and 
100 units/mL LIF (produced in house) at 37 ºC in 5% CO2. 
Generation of 3HA-tag N567K mES cell line 
For the generation of the 3HA mES cell line, we transfected wild type male E14-TG2a.IV 
AW2 mES cells with pBABED puro U6 and pX335 (Cas9 D10A) vectors containing the 
gRNA sequences selected using WTSI Genome Editing [58]. Silent mutations were 
designed in addition to the intended mutations, removing PstI and BfmI restriction sites 
(Supplementary Fig. 2). A geneblock containing these changes was obtained from IDT 
(International DNA technologies). The geneblock was introduced into the cloned 2 kb 
region by restriction free cloning [59] and then confirmed by DNA sequencing [59]. For 
transfection, 2x105 cells were seeded onto gelatine coated 24-well plates and transfected 
using 0.33 µg of each vector and Lipofectamine 3000 according to manufacturer’s 
instructions. After 24 h, media was replaced and puromycin (3 µg/mL) was added to the 
cells for selection until control untrasfected cells were all dead (48 h). Then the cells ware 
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using limited dilution according to 0.3 cell per well in 96 well plates. For confirmation of 
mutations, diagnostic restriction digests and genomic DNA sequencing analysis were 
carried out. For the restriction fragment length polymorphism assay 3HADiag_F and 
3HADiag_R primers were used to amplify by PCR the mutated site and the silent 
mutation which eliminates a PstI restriction site (Supplementary Table S1). The size of 
the PCR product (546 bp vs 450 bp for wild type) was used to screen for successful 
integration. To further confirm, the PCR product was then digested using PstI or BfmI. 
Clones negative for the restriction enzyme assay were then sequenced to confirm the 
presence of the modification.
For generation of the 3HA-OGTN648Y mESCs, we transfected the previously generated 
3HA mESCs with pBABED puro U6 and pX335 (Cas9 D10A) vectors containing the 
gRNA sequences using the same procedure we previously used for the insertion of the 
3HA-tag (Supplementary Fig. 3). Restriction enzymes and genomic DNA sequencing 
analysis were used for mutation identification. For the restriction fragment length 
polymorphism assay MouseEstDiag_F and MouseEstDiag_R primers were used to 
amplify by PCR the mutated site and the silent mutation which eliminates an Eco130I 
restriction site (Supplementary Table S2). The size of the bands following digestion (167 
bp and 433 bp for wild type versus 600 bp for mutant) was used to screen for successful 
integration. Clones negative for cutting in the restriction enzyme assay were then 
sequenced to confirm the presence of the modification.
Western Blot
Cells were harvested in lysis buffer containing 150 mM NaCl, 1% Nonidet P-40, 0.5% 
Sodium deoxycholate, 0.1% Sodium dodecyl sulfate, 25 mM TrisHCl (pH 7.4), 1 mM 
Sodium orthovanadate, 50 mM Sodium fluoride, 5 mM Sodium pyrophosphate. 10-20 µg 
of cell lysate was loaded in NuPAGE 3-8% Tris-Acetate gels (Invitrogen) and transferred 
to Nitrocellulose membranes using wet transfer system. Membranes were blocked with 
TBS-T 5% BSA buffer [w/v]. Primary antibodies used were OGT (F-12, Santa Cruz 
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Figure legends
Figure 1: Clinical pictures from patient carrying the N648Y mutation in the catalytic 
domain of OGT
(a) Facial asymmetry at birth
(b) Facial view at 7 y.
(c) Profile view at 7 y. Note coarse facial features, drooling.
(d) MRI image showing brain atrophy and mega cisterna magna.
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Figure 2: Effects of the N648Y mutation on OGT structure and activity.
(a) Schematic diagram of OGT highlighting the TPRs, TPR-like repeat, the Catalytic 
domain, the N648Y mutation (bold) and all the previous identified mutations in 
OGT. TPR: tetratricopeptide repeat domain; TLR; tetratricopeptide repeat-like 
domain.
(b) Immunoblots showing OGT glycosyltransferase activity against TAB1 and gTAB1. 
Quantification of gTAB1 normalised to TAB1 signal. N = 3, mean ± SD. Multiple t-
test using the Holm-Sidak method. * corresponds to p = 0.021 (2 mins), p = 0.017 
(5 mins) and p = 0.008 (50 mins) TAB1:TAK1-binding protein antibody; gTAB1: 
glycosylated TAB1 antibody.
(c) OGT superimposed complexes of OGTWT (In light gray; PDB: 5C1D; [43]) and 
OGTN648Y (In blue; PDB: 6Q4M) showing the mutated site and the proximal 
residues. N648Y mutated residue is shown in red.
(d)
OGTN648Y in complex with superimposed RB2 peptide from OGTWT (PDB: 5C1D) 
showing the putative location of the peptide. The loop 642-648 of OGTN648Y is 
indicated including the distance from the superimposed peptide.
(e)




Figure 3: The N648Y mutation leads to reduced protein O-GlcNAcylation in 3HA-
N648Y mES cells. 
(a) Immunoblots showing OGA, protein O-GlcNAcylation (RL2) and OGT levels in 
3HA-WT and 3HA-N648Y undifferentiated mES cells. 
(b) Quantification of Western blotting of OGA, protein O-GlcNAcylation (RL2) and 
OGT levels normalised to tubulin signal. n = 3, mean ± SD. Unpaired t-test. ** 
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Table 1: X-ray diffraction data processing and refinement statistics of the 
OGTN648Y ternary complex. 
Numbers in brackets show represent the highest resolution bin.  
 
 OGTN648Y 




   α, β, γ () 137.3, 150.7, 199.5 
Resolution (Å) 45.92 – 2.27 (2.20 – 
2.27) 
Rsym or Rmerge 0.08 (0.87) 
I / σI 12.0 (2.0) 
Completeness (%) 100 (99) 
Redundancy 6.7 (6.7) 
No. reflections 52373 (819) 
Rwork / Rfree 0.17 / 0.20 
R. M. S. 
DEVIATIONS 
 
    Bond lengths 
(Å) 
0.011 
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